Sign in
Not yet recruitingPhase 2

Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy

Key facts

Who runs it
University Hospital, Strasbourg, France
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
120 people, planned
Starts
1 Aug 2027
Expected to end
31 Dec 2032
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • • Sivelestat intravenous infusion
  • NaCl intravenous infusion
Record updated
20 August 2026

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Adults aged 18 to 85 years
  • Patient (male or female) admitted to the ICU with:; Septic shock defined by Sepsis-3 criteria: acute, life-threatening organ dysfunction related to a suspected or confirmed infection, requiring vasopressor support to maintain a mean arterial pressure ≥ 65 mmHg and a serum lactate level > 2 mmol/L despite adequate fluid resuscitation; Coagulopathy defined by a SIC score ≥ 4 points
  • Randomization within 12 hours after the diagnosis of coagulopathy (positive SIC score)
  • Patient affiliated with a national health insurance system
  • Written informed consent: freely given, dated, and signed; By the patient; Or by a legal representative if the patient is unable to provide consent; Or through an emergency inclusion procedure if the patient is unable to consent and no family member is available

Who cannot take part

  • Participation in another interventional drug clinical trial
  • History of hypersensitivity reaction to Sivelestat (the only contraindication for Sivelestat)
  • Severe chronic liver disease (Child-Pugh C)
  • Patient weight > 100 kg
  • Contraindication to the use of unfractionated heparin
  • Moribund patient at the time of randomization
  • Limitation of active therapeutic interventions at the time of study inclusion
  • Under legal protection (guardianship, curatorship, or legal safeguard)
  • Pregnancy or breastfeeding

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Sepsis-induced disseminated intravascular coagulation (DIC) is a severe complication occurring in one-third of patients with septic shock, for which no specific treatment currently exists. It results from excessive systemic activation of coagulation and impaired fibrinolysis, leading to the development of disseminated microthromboses. We have recently demonstrated: 1) the contribution of NETs to the hypercoagulability observed in DIC, and 2) the role of neutrophil elastase-bound to NET DNA-in degrading plasminogen, a key factor limiting fibrinolysis and thus preventing the lysis of microthrombi in DIC.

Read full original descriptionShow less

Sivelestat is a neutrophil elastase inhibitor used in Japan for the treatment of acute respiratory distress syndrome (ARDS). It has the potential to inhibit: 1) neutrophil activation and the release of inflammatory mediators, and 2) plasminogen degradation, which drives fibrinolytic failure. A recent meta-analysis including 2,050 patients across 15 studies showed that Sivelestat reduced ARDS patient mortality at day 28-30 (RR = 0.81, 95% CI = 0.66-0.98, p = 0.03), decreased mechanical ventilation duration and ICU length of stay, and improved oxygenation.

We propose to conduct a multicenter, double-blind, placebo-controlled phase IIb trial evaluating the efficacy of Sivelestat in restoring fibrinolysis in patients with septic shock complicated by coagulopathy, defined by a positive SIC score (≥ 4 points).

The 2 groups in the trial

  • Active therapyTreatment being tested

    • Sivelestat

    Treatment: • Sivelestat intravenous infusion

  • Placebo therapyPlacebo, for comparison

    • NaCl

    Treatment: NaCl intravenous infusion

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07214103, who can take part
Record updated
20 August 2026